DCM
IMUC

DAFNA Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

DAFNA Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-14,167
Closed -$691K – 54
2014
Q1 		$691K Buy
+14,167
New +$693K 0.59% 32

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DAFNA Capital Management's IMUC Position: Q2 2014 in Review

DAFNA Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2014, closing a stake of 14,167 shares — an estimated $691K sold.

DAFNA Capital Management first reported a position in IMUC in Q1 2014 and held it in 1 quarter. The position peaked at $691K in Q1 2014. 42 funds tracked by Wall St. Rank hold IMUC as of Q2 2014.

  • DAFNA Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2014 after selling out during the quarter.
  • DAFNA Capital Management sold 14,167 ImmunoCellular Therapeutics, Ltd. shares in Q2 2014, an estimated $691K.
  • DAFNA Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q1 2014 and held it in 1 quarter.
  • DAFNA Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $691K in Q1 2014.
  • 42 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2014.

Based on DAFNA Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.